Introduction {#S1}
============

Amyotrophic lateral sclerosis (ALS) is a devastating adult-onset neurodegenerative disorder ([@B28]). Both the upper and lower motor neurons (MNs) are affected, such that the disorder is characterized by muscle weakness with spasticity and atrophy. Approximately 10% of ALS occurrence is familial ([@B66]). Since the identification in 1993 ([@B171]) of *copper/zinc superoxide dismutase 1* (*SOD1*) in ALS patients with an autosomal dominant trait in 1993 ([@B8]), more than 25 genes have been reported as causative genes of familial ALS ([@B121]; [@B45]; [@B66]; [@B38]).

The pathomechanisms of ALS have been examined using familial ALS models. Intracellular generation of reactive oxygen species production ([@B22]; [@B217]; [@B81]) and unfolded protein response/endoplasmic reticulum (ER) stress ([@B101]; [@B100]; [@B205]) have been inferred from the discovery of SOD1 as a factor. A cell non-autonomous effect ([@B20]; [@B49]; [@B141]; [@B226]; [@B43]) has also been examined in mutant *SOD1*-transgenic mouse and cellular models. Mutations in the RNA-binding protein (RBP) *TAR DNA-binding protein* (*TARDBP* encoding TDP-43) can result in ALS ([@B91]; [@B175]), and cytoplasmic TDP-43 inclusions have been reported in over 90% of cases of sporadic ALS ([@B119]). In 2009, *fused in sarcoma* (*FUS*) was determined in 2009 to be the causative gene of ALS ([@B106]; [@B206]). FUS and TDP-43 have similar structural characteristics, including an RNA recognition motif (RRM), a nuclear export signal (NES), a nuclear localization signal (NLS), and prion-like domains (PrLDs) ([@B96]). The C-terminal NLS site regulates the nucleocytoplasmic localization of FUS and is a hotspot for mutations in familial ALS ([@B106]; [@B206]; [@B195]; [@B149]). Abnormal phase separation of FUS is involved in this pathomechanism ([@B71]; [@B79]; [@B166]). NLS mutations impair the nuclear import of FUS, and the level of mislocalized cytoplasmic FUS is correlated to the severity of the clinical ALS phenotypes ([@B50]). In addition, recent reports have demonstrated that the abnormal NLS function results in the aberrant accumulation of mutant FUS in the cytoplasm ([@B82]; [@B71]; [@B79]; [@B166]; [@B231]). Previous studies have found that the toxic gain of function occurring with mutant *FUS* is crucial for neurodegeneration ([@B180]; [@B184]; [@B186]).

A hexanucleotide repeat expansion in *chromosome 9 open reading frame 72* (*C9orf72*) ([@B47]; [@B169]) is the most common cause of ALS when examined in Western countries ([@B11]). Loss of function of C9ORF72 ([@B30]; [@B153]), toxic gain of function of C9ORF72 due to repeat RNA ([@B158]; [@B85]), and toxic gain of function due to proteins with dipeptide repeats resulting from repeat-associated non-ATG translation ([@B136]; [@B107]; [@B132]; [@B214]; [@B34]) have been suggested as disease mechanisms.

These findings are mainly focused on the event in the cytoplasm of MNs. Actually, long axons, which have lengths of up to 100 cm in humans, are characteristic of MN morphology, and connect the soma of MNs to the skeletal muscles. In ALS, MNs are dysfunctional due to axonal degeneration ([@B56]), that occurs prior to the motor phenotype in ALS ([@B59]; [@B174]). Consistent with this observation, transgenic models of ALS also demonstrate abnormal axons and other degenerative processes, followed by the death of MNs ([@B9]; [@B204]; [@B62]). Other studies have revealed that axonal damage occurs earlier than the death of cell bodies and subsequent symptoms in patients; such symptoms become apparent only after the loss of many MNs ([@B42]).

Various reviews have described the physiological and pathological features of neuronal axons, including cargo transport within axons, local translation, and the axonal transcriptome ([@B89]; [@B121]; [@B14]; [@B145]; [@B23]; [@B45]). However, because primary neurons from patients cannot be easily obtained and because axons produce low sample yields and are difficult to culture, the details of the pathological mechanisms of ALS remain unclear. To further elucidate the resilience and pathomechanisms in MN axons, this review summarizes omics analyses of the axon compartment using microfluidic devices and *ex vivo* samples. Intra-axonal transcription and local axonal translation are the mechanisms of ALS emerging in the field, as discussed in the following.

Accumulating Evidence of Axonal Dysfunction in ALS {#S2}
==================================================

The global pathomechanisms of axons in ALS are considered next, in an overview of the current knowledge of axonal events in MNs. This section classifies the pathomechanisms of axonal dysfunction into six subsections, including neuronal cytoskeleton, cargo transport within axons, axonal energy supply, clearance of junk protein, neuromuscular junctions (NMJs), and aberrant axonal branching ([Figure 1](#F1){ref-type="fig"}). As mentioned in the introduction, an increasing number of genes have been found as causative or associated genes for ALS. Evidence of axon pathomechanisms from the genetics of ALS is also accumulating ([Table 1](#T1){ref-type="table"}). These mechanisms are explained in each subsection.

![Proposed pathomechanism of ALS in axon compartments. (1) Neuronal cytoskeleton; (2) cargo transport within axons; (3) axonal energy supply; (4) clearance of junk protein; (5) Neuromuscular junction (NMJs); (6) aberrant axonal branching; (7) Axonal translation; (8) Intra-axonal transcription factors are prominent features of the proposed pathomechanism.](fnins-14-00194-g001){#F1}

###### 

Motor neuron disease-associated mutations and axonal pathology.

  Disease                     Gene      Protein                                                    Axonal pathology
  --------------------------- --------- ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------
  ALS1                        SOD1      Superoxide dismutase 1                                     Impaired transport of mitochondria, microtubule stability, modulation of motor proteins via p38 MAP kinase etc.
  ALS2                        ALS2      Alsin                                                      Impaired endocytic trafficking, signaling endosomes
  ALS5/SPG11                  SPG11     Spatacsin                                                  Axonal destabilization, reduced tubulin acetylation, reduced anterograde vesicle transport
  ALS6                        FUS       FUS                                                        Defective transport of mitochondria, aberrant microtubule acetylation, NMJ deformity, aberrant axon branching, Fos-B overexpression
  ALS8                        VAPB      Vesicle-associated membrane protein-associated protein B   Impaired transport of mitochondria and vesicles
  ALS10                       TARDBP    TAR DNA-binding protein 43                                 Defective transport of mitochondria and mRNP granules; reduced expression of dynactin 1; aberrant microtubule stability/acetylation
  ALS17                       CHMP2B    Charged multivesicular body protein 2B                     Impaired endocytic trafficking, signaling endosomes
  ALS12                       OPTN      optineurin                                                 Progressive dysmyelination and axonal degeneration through engagement of necroptotic machinery in the CNS, including RIPK1
  ALS18                       PFN1      Profilin l                                                 Decreased bound actin levels and can inhibit axon outgrowth. Primary motor neurons expressing mutant PFN1 display smaller
  ALS22                       TUBA4A    Tubulin, alpha 4a                                          Destabilization of microtubules, general transport defect
  ALS23                       ANXA11    annexin All                                                Molecular tether between lysosomes and RNA granules in axon
  ALS25/SPGIO                 KIF5A     Kinesin heavy chain                                        Reduced kinesin-1 mediated transport, impaired neurofilament transport
  FALS/HMN7B/Perry syndrome   DCTN1     Dynactin 1 (p150, glued homolog, Drosophila)               Altered axonal transport and vesicle trafficking, impaired signaling endosome trafficking
  FTDALS1                     C9orf72   C90RF72                                                    Defective transport of mitochondria
  SPG4                        SPAST     Spastin                                                    Destabilization of microtubules, impaired transport of mitochondria and vesicles
  SPG30                       KIF1A     Kinesin Family Member 1A                                   Reduced kinesin-3 mediated transport
  SBMA                        AR        Androgen receptor                                          Defective retrograde and anterograde transport, modulation of motor proteins via JNK

Modified from

Maday et al. (2014)

;
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, and

Ghasemi and Brown (2018)

. Also refer to OMIM (

https://www.omim.org/

) as of June 2019.

Neuronal Cytoskeleton {#S2.SS1}
---------------------

The axon can be visualized as a railway, and the electric signal should be transferred from one train terminal station (the cell body) to another terminal station (the skeletal muscle). Mutations in genes associated with microtubules have been identified as the causative events in ALS.

Several variants of the gene encoding α-tubulin, *TUBA4A*, destabilize the microtubule network and reduce the repolymerization capability of this network ([@B188]). A missense mutation in the *tubulin-specific chaperone E* gene, causing MN degeneration in the progressive motor neuronopathy model mouse, ends in microtubule and axonal defects similar to those induced by the ALS-linked *TUBA4A* variation in patients ([@B21]; [@B124]).

Mutations in *profilin 1* (*PFN1*) can also lead to familial ALS. PFN1 converts monomeric actin to filamentous actin. Ubiquitinated aggregates are present in cells that express mutant *PFN1*, and many of these aggregates include TDP-43, which is associated with ALS ([@B221]). Such cells also have lower levels of bound actin and block axon growth. Primary MNs that harbor mutant *PFN1* have a lower ratio of monomeric to filamentous actin and smaller growth cones. The PFN1 transgenic mouse has also been observed to recapitulate the phenotype of MN disease ([@B58]).

NIMA (never in mitosis gene A)-related kinase 1 (NEK1) has been linked to cilia formation, microtubule stability, and neuronal morphology ([@B202]). The *NEK1* gene was identified as a susceptibility factor for ALS ([@B24]; [@B99]). Using *in vivo* imaging, axonal degeneration was identified as an early event in the *SOD1* and *C9ORF72* repeat expansion mouse models of ALS ([@B204]). Neurofilament L transcripts are reduced in ALS ([@B16]). Neurofilaments are also found in a spheroid structure (large axonal swelling) ([@B39]). Neurofilament light (NFL) and phosphorylated neurofilament heavy (pNFH) are also known as biomarkers for ALS ([@B26]; [@B193]).

Thus, a dysfunctional cytoskeleton plays a role in ALS pathogenesis.

Cargo Transport Within Axons {#S2.SS2}
----------------------------

Maintenance of the function and structure of all types of cells in mammals requires the intracellular transport of cargo. This transport is especially important in neurons because of their axonal and cell body polarization ([@B45]). Proteins and mRNA, as well as organelles, are generally synthesized in the soma and transported along the axon. Proper transport is required for the distribution of this cargo at the right time and place in the axon. Using electron microscopy of autopsy samples from ALS cases, defects in the cargo transport within axon transport in ALS have been observed. The studies of this transport defect revealed that the proximal axons of large MNs harbor abnormal accumulation of mitochondria, phosphorylated neurofilaments, and lysosomes ([@B77], [@B78]; [@B151]; [@B173]). In addition, spheroids present in the axons contain different types of vesicles, lysosomes, mitochondria, neurofilaments, and microtubules ([@B45]). The accumulation of phosphorylated neurofilaments at the initial segment of MN axons is a major pathological characteristic of ALS ([@B1]; [@B23]).

Aberrant cargo transport within axons occurs early in ALS disease progression ([@B218]; [@B44]). For example, an altered transport of mitochondria in axons has been demonstrated in two different mutant *SOD1*-G93A transgenic mouse models of ALS ([@B122]). The slow anterograde transport of cytoskeletal components is decreased during the months prior to the initial neurodegeneration in mutant *SOD1*-G37R transgenic mice, a change that has been exhibited using metabolic labeling studies ([@B218]). In mutant *SOD1*-G93A transgenic mouse models, inhibiting p38 MAPK α rescues retrograde cargo transport defects within axons ([@B67]).

TDP-43 functions as an mRNA transporter across the axonal cytoskeleton, and ALS-related mutations in TDP-43 alter this transport function ([@B4]). Mitotracker and Lysotracker experiments in *FUS*-mutant iPSC-derived MNs have demonstrated that defects in the cargo transport within axons can be rescued by histone deacetylase 6 inhibition ([@B72]).

Mutations in the genes that code for the motor protein dynactin (*DCTN1*) ([@B165]) have been identified in the genetic analyses of familial ALS. Mutant dynactin binds weakly to microtubules, compared with the binding of wild-type proteins. ALS and slowly progressing, autosomal dominant, distal hereditary motor neuropathy in vocal paresis (HMN7B) are due to loss-of-function mutations in *DCTN1* ([@B165]; [@B140]; [@B228]). DCTN1 expression is also found to be downregulated in ALS-derived autopsy samples ([@B86]).

*Kinesin family member 5A* (*KIF5A*) is a newly identified gene that plays a role in ALS ([@B25]; [@B146]). Mutations that occur in the N-terminal motor domain of KIF5A cause an autosomal dominant type of hereditary spastic paraplegia known as spastic paraplegia (SPG)10, as well as Charcot--Marie--Tooth disease type 2 ([@B57]). In contrast, mutations associated with ALS are mainly found in the C-terminal domain, which is important for binding cargo. Patients with loss-of-function *KIF5A* mutations have longer survival times than those with typical ALS ([@B25]; [@B146]). Mutations in *KIF5A*, as well as *KIF1A*, which are loss-of-function mutations, are present in the motor or neck domains ([@B51]; [@B37]).

In addition to MNs, mature sensory axons also possess a complex series of mRNA. A microtubule-stabilizing agent, paclitaxel, which impairs cargo transport within axons, results in sensory neuropathy ([@B70]). Defects in the cargo transport within axons are common to various neurodegenerative diseases. Impaired cargo transport in axons can cause neurodegeneration ([@B131]).

Axonal Energy Supply {#S2.SS3}
--------------------

The mitochondria play an important role in meeting the axonal energy demand as they generate ATP through oxidative phosphorylation ([@B33]). Following their synthesis in the cell body, the mitochondria enter the axon where they undergo robust trafficking and accumulate at the nodes of Ranvier to meet metabolic needs ([@B232]). Disruption of the mitochondrial activity, transport proteins, and microtubule association likely leads to dysfunctional mitochondrial transport in neurodegenerative diseases. Energy deficits in injured axons are caused by damage to the mitochondria following damage to axons, a decrease in mitochondrial transport in axons of mature neurons, and an increased energy consumption ([@B234]). During regeneration, the axons adapt to this increased energy demand by changing the dynamics of the mitochondria ([@B103]). Mutations in *RAPGEF2* mutations impair microtubule stability and the mitochondria distribution in axons ([@B76]). Reduction in mitochondrial Rho GTPase 1 (Miro 1), the outer mitochondrial membrane protein, leads to anterograde axonal transport defects ([@B133]). The imbalance between mitochondrial fission and fusion leads to abnormal mitochondrial morphology, underlies axonal damage, and is a potential therapeutic target for treating SPG15 and SPG48 ([@B48]). The ER and mitochondria form complex sites of interactions known as mitochondria-associated membranes ([@B65]). Decreased ER-mitochondria association can occur as a result of loss-of-function mutations in *SIGMAR1*, leading to impaired retrograde transport and, ultimately, to axonal degeneration and MN death ([@B17]; [@B213]).

Astrocytes and oligodendrocytes may meet the axonal energy demand ([@B94]; [@B111]; [@B139]). A deficiency in monocarboxylate transporter 1 (MCT1) was observed in oligodendroglia in the ventral cord of *SOD1* transgenic mice and in the motor cortex of ALS patients ([@B95]; [@B159]). The removal of the *SOD1* mutation from oligodendroglial precursor cells was observed to result in marked attenuation of the progression of the disease ([@B95]). Reducing the expression of *MCT1* in oligodendroglia is the pathomechanism involving the energy supply that contributes to MN degeneration in ALS.

Clearance of Junk Protein {#S2.SS4}
-------------------------

The ubiquitin proteasome and autophagy clearance systems are significant homeostatic processes engaged in eliminating defective organelles and aggregated proteins throughout the life span of the neuron. Impairment of the ubiquitin proteasome degradation system in MNs has been reported to replicate the ALS phenotype in mice ([@B199]). Mice with MN-specific, conditional knockout of the proteasome subunit *Rpt3* exhibit locomotor dysfunction, progressive MN loss, and gliosis ([@B199]). Constitutive autophagy in neurons also maintains cellular homeostasis by balancing the synthesis and degradation of proteins, particularly within the distal axonal processes ([@B120]). Several genes, such as *valosin-containing protein*, are involved in the protein degradation process ([@B87]).

What about in the axon fraction? Disruption of the endosomal-lysosomal system due to ALS2/Alsin loss exacerbates the phenotype of *SOD1*-H46R transgenic mice by accelerating the accumulation of misfolded proteins and immature vesicles in the spinal cord ([@B73]). In the early symptomatic and even presymptomatic *SOD1*-H46R transgenic mice, degenerating and swollen spinal axons with the accumulation of autophagosome-like vesicles have been observed ([@B73]). A recent study also reported impairment of the degradation of autophagic vacuoles that engulf damaged mitochondria from distal axons in the *SOD1*-G93A transgenic mouse model ([@B224]). The clearance of dysfunctional mitochondria from axons may be mediated by syntaphilin, a mitochondria-anchoring protein, which is expressed at high levels in the early disease stages of ALS in MNs ([@B114]). *FUS* mutation causes axonal retention of the FUS protein prior to its aggregation, which is caused by poly(ADP-ribose) polymerase-dependent DNA response signaling ([@B143]). The authors of this review also observed the accumulation of mutant FUS protein in the neurites of *FUS*-mutant induced pluripotent stem cell (iPSC)-derived MNs ([@B3]).

*Optineurin* (*OPTN*) mutations are implicated in both familial and sporadic ALS ([@B126]). OPTN binds to ubiquitin and regulates NFκB activation and apoptosis ([@B142]). OPTN is also involved in several selective autophagy processes regulated by TBK1 ([@B112]). Receptor-interacting kinase (RIPK) 1-dependent signaling is suppressed by OPTN through the regulation of its turnover ([@B83]). OPTN loss leads to progressive demyelination and axonal degeneration through the activation of necroptotic machinery in the central nervous system (CNS) ([@B83]). These observations suggest that RIPK1 and RIPK3 are significant in the process of progressive axonal degeneration.

A novel variant in *UBQLN4* compromises motor axon morphogenesis in zebrafish, impairing the proteasomal function ([@B52]; [@B138]). Based on these reports, the clearance of junk protein is important in the compartment of the MN axon.

NMJs {#S2.SS5}
----

Amyotrophic lateral sclerosis can be redefined as a distal axonopathy disease, because many molecular changes influencing MN degeneration occur at the NMJ ([@B134]). The NMJ is a highly specialized synapse, that controls signals between muscles and nerves for skeletal muscle function. Neuromuscular remodeling precedes loss of the motor unit in the mutant *SOD1*-G37R transgenic mouse model ([@B125]).

Certain molecules, including galectin-1 ([@B55]; [@B161]), CD44 ([@B181]), and amyloid precursor protein ([@B29]), affect the function of NMJ. Axon guidance molecules affecting the stability of the cytoskeleton, such as Semaphorin 3A ([@B207]), Ephrin A4 ([@B197]), and Nogo-A ([@B164]), have been reported to alter the function of the NMJ in the early stage of ALS. The loss of mitofusin 2 in neurons causes NMJ dysfunction, whereas the upregulation of mitofusin 2 ameliorates the phenotype of mutant *SOD1*-G93A transgenic mice ([@B212]).

The expression of mutant *FUS* or *FUS* knockdown in zebrafish results in the impairment of motor activity and reduces quantal transmission at NMJs, indicating loss and gain of function of FUS ([@B9]). These changes in FUS culminate in presynaptic dysfunction at the NMJ ([@B9]). There is evidence that FUS plays multiple roles in the nucleus and axonal compartments involved in NMJ maintenance and axonal transport ([@B182]; [@B190]). FUS mediates the regulation of acetylcholine receptor transcription at NMJ and is dysregulated in ALS ([@B160]).

C9ORF72 was identified on the presynaptic side where the protein interacts with Rab3 protein family members, suggesting that it has a role in the regulation of synaptic vesicle functions as a guanine nucleotide exchange factor ([@B61]).

In *Drosophila*, the protein Arc1 is a component of the capsid-like structures that bind *DARC1* mRNA in neurons. These capsids are included in the extracellular vesicles that are transferred across the NMJ from MNs to the muscle cells ([@B10]). The transport of mRNA across the NMJ via these retrovirus-like capsids and extracellular vesicles is required for synaptic plasticity ([@B10]). Dipeptide repeat proteins related to C9ORF72 spread between cells *in vitro* and *in vivo* ([@B216]). Tau is another protein that is transported from donor cells to recipient cells through the cell culture medium ([@B222]). Evidence suggests that the mechanism of pathogenic molecular transfer, termed the prion hypothesis, may be activated in the extracellular space and across the NMJ synapses during degeneration of the motor cortex with centrifugal spreading ([@B63]; [@B150]; [@B162]).

Aberrant Axonal Branching {#S2.SS6}
-------------------------

Axonal branching is a fundamental mechanism of nervous system neuroplasticity ([@B129]). Accumulating evidence suggests that aberrant axonal branching is involved in the pathomechanisms of ALS.

Overexpression of mutant human *TARDBP* in zebrafish embryos induces a phenotype that includes shorter MN axons, premature and increased branching, and abnormal swimming ([@B90]). On the other hand, overexpression of progranulin rescues mutant *TARDBP*-induced aberrant axonal branching and short axonal outgrowth ([@B110]).

Injection of morpholino antisense oligonucleotides to inhibit the translation of target mRNA and to knock down *SMN* in zebrafish embryos significantly increases MN branching ([@B127]). C9ORF72 modulates the activity of the small GTPases, resulting in increased activity of LIM kinases 1 and 2 and regulation of axonal actin dynamics ([@B187]). Various actin isoforms are expressed in primary mouse MNs, and their transcripts have been observed to be translocated into axons ([@B135]). It is proposed that short hairpin RNA-mediated depletion of α-*actin* reduces axonal filopodia dynamics and disrupts collateral branch formation in developing MNs ([@B135]).

Temporary overexpression of human cyclin-F (*CCNF)* in zebrafish embryos increases the levels of cleaved caspase-3 and cell death in the spinal cord. The mutant *CCNF* zebrafish also developed an MN axonopathy, which consists of shortened primary MN axons and an increased frequency of aberrant axonal branching ([@B80]).

A recent study reported that MNs cultured from mutant *SOD1*-G93A transgenic mouse models exhibit enhanced axonal outgrowth and dendritic branching ([@B154]). As the level of branching does not correlate with the severity of the disease, in this study, the authors concluded that axonal branching does not affect the disease process. Increased synaptic activity or branching is considered desirable in the field of psychiatric disease ([@B183]). The authors of the present review identified aberrant axonal branching in *FUS*-mutant iPSC-derived MNs ([@B3]). The sensory axons branching in the presence of nerve growth factor (NGF) can be observed at sites marked by stalled mitochondria. NGF promotes branching through the generation of ATP and active axonal translation of mRNA ([@B192]). The mechanism underlying mitochondrial stalling and growth factor distribution in MNs requires examination.

The meaning of axonal branching might be different in each stage of the development ([@B89]). In the embryonic stage, axon pathfinding and synaptic formation are important. However, in the developed stage, aberrant axon branching might have a disadvantage in terms of normal function of signal transmission. The significance of aberrant axonal branching in the neurodegenerative model *in vivo* has not yet been elucidated.

Omics Profiling of the Axonal Compartment {#S3}
=========================================

The previous section provided an overview of the important pathomechanisms of MN axons. These pathomechanisms have been found to influence each other and cannot be entirely separated. This section reviews the omics analysis of the axon compartment in order to obtain an overall understanding of this complex process occurring in an important region of the neuron.

Lessons From Different Nervous Systems {#S3.SS1}
--------------------------------------

The rationale for conducting omics analysis of the axon compartment is as follows ([Table 2](#T2){ref-type="table"}). Surprisingly complex, constantly changing transcriptomes are present in mature axons. Thus, axonal mRNA localization is likely to be tightly regulated and to play multiple roles. The ribosomal protein S6 has been observed with immunoelectron microscopy in the axons of embryonic sympathetic and hippocampal neurons grown *in vitro* ([@B201]), indicating that local mRNA translation also occurs in growing axons. Further, the local translation of proteins from mRNAs selectively transported from the soma to the synaptic terminal appears to be involved in the regulation of axon outgrowth and regeneration ([@B233]; [@B200]).

###### 

Omics analyses of the axon compartment in *in vivo*, *ex vivo*, and *in vitro* models of several types of nervous systems.

  Disease modeling   System     Cell resource                                                                                                                                                   *Vivo/Vitro*   Methodology                                                                                                                                                                                                                       Analysis                                                                                                                                                                                   Core result                                                                                                                                                                                                                                                                                                                                                                                          References
  ------------------ ---------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  ALS                Motor      Human iPS-derived motor neuron                                                                                                                                  *in vitro*     Separating axon using microfluidics (Jiksak Bioengineering)                                                                                                                                                                       RNA sequencing                                                                                                                                                                             Increased level of Fos-B mRNA, the binding target of FUS, in FUS-mutant MNs. While Fos-B reduction using si-RNA or an inhibitor ameliorated the observed aberrant axon branching, Fos-B overexpression resulted in aberrant axon branching even in zebrafish model.                                                                                                                                  [@B3]
  ALS                Motor      Mouse and human stem cell-derived spinal motor axons                                                                                                            *in vitro*     Microfluidics                                                                                                                                                                                                                     RNA sequencing                                                                                                                                                                             Identified 3,500--5,000 transcripts in mouse and human stem cell-derived spinal motor axons, most of which are required for oxidative energy production and ribogenesis. Axons contained transcription factor mRNAs, e.g., Ybx1, with implications for local functions. In SOD1G93A mutant, identifying 121 ALS-dysregulated transcript, including Nrp1, Dbn1, and Nek1, a known ALS-causing gene.   [@B147]
  No                 Motor      hiPSC-derived motor neuron                                                                                                                                      *in vitro*     Permeable inserts culture device                                                                                                                                                                                                  RNA sequencing                                                                                                                                                                             Discriminate axonal and somatodendritic compartments                                                                                                                                                                                                                                                                                                                                                 [@B117]
  No                 Retina     Retinal ganglion cells (RGCs) exit from the eye primordia from Xenopus laevis embryos                                                                           *Ex vivo*      Axon grow through the 1 μm pores of the transfilter on the Boyden chamber                                                                                                                                                         Pulsed stable isotope labeling of amino acids in cell culture (pSILAC) with ultrasensitive sample preparation technology termed single-pot solid-phase-enhanced sample preparation (SP3)   Axons stimulated by different cues (netrin-1, BDNF, Sema3A) showed distinct signatures with over 100 different nascent protein species                                                                                                                                                                                                                                                               [@B31]
  ALS                Spinal     Dissociated spinal cord culture from ICR mice at E12.5                                                                                                          *Ex vivo*      Modified boyden chamber membrane culture system                                                                                                                                                                                   RNA sequencing                                                                                                                                                                             Elavl2 and miR-146a, miR-126-5p, miR-99a are shared in axons of lentiviral overexpression of both p.A315T TARDBP and p.G93A SOD1 mutants.                                                                                                                                                                                                                                                            [@B172]
  No                 Neuron     Differentiated neurons from human ESC                                                                                                                           *in vitro*     Microfluidics                                                                                                                                                                                                                     Microarray                                                                                                                                                                                 Confirmed the presence of two well characterized axonal mRNAs in model organisms, β-actin and GAP43, within hESC-neuron projections. oxytocin mRNA localized to these human projections and confirmed its localization using RNA-FISH.                                                                                                                                                               [@B19]
  No                 Motor      Isolated motor neuron from E12.5 CD-1 mouse spinal cord using p75NTR antibody panning                                                                           *Ex vivo*      Xona microfluidics, SND 150 chamber                                                                                                                                                                                               RNA sequencing                                                                                                                                                                             Double-random priming transcriptome methods enable to serially diluted total RNA down to 10 pg                                                                                                                                                                                                                                                                                                       [@B27]
  No                 Retina     Retinal ganglion cells (RGCs) of mouse                                                                                                                          *in vivo*      Axonal translatome using Axon-TRAP-RiboTag mouse and IP of ribosome mRNAs                                                                                                                                                         *in vivo* axonal translatome                                                                                                                                                               The embryonic to postnatal axonal translatome comprises an evolving subset of enriched genes with axon-specific roles, suggesting distinct steps in axon wiring, such as elongation, pruning, and synaptogenesis. Adult axons have a complex translatome with strong links to axon survival, neurotransmission and neurodegenerative disease.                                                        [@B185]
  SMA                Motor      Isolated motor neuron from E12.5 CD-1 mouse spinal cord using p75NTR antibody panning                                                                           *Ex vivo*      Xona microfluidics, SND 150 chamber                                                                                                                                                                                               Microarray                                                                                                                                                                                 Knockdown of SMN, the protein deficient in spinal muscular atrophy, produced a large number of transcript alterations in both compartments. Transcripts associated with axon growth and synaptic activity were down-regulated on the axonal side of smn- deficient motor neurons.                                                                                                                    [@B176]
  No                 Retina     DRG explants dissected from embryonic (E16) and adult (3--5 mo old) from Sprague Dawley rats                                                                    *Ex vivo*      Compartmentalized chamber to isolate mRNA from pure embryonic and adult sensory axons devoid of non-neuronal or cell body contamination                                                                                           Genome-wide microarray                                                                                                                                                                     Tubulin-beta3 (Tubb3) mRNA is present only in embryonic axons, with Tubb3 locally synthesized in axons of embryonic, but not adult neurons where it is transported                                                                                                                                                                                                                                   [@B70]
  No                 Retina     Retinal ganglion cell (RGC) axons of two vertebrate species, mouse and Xenopus                                                                                  *Ex vivo*      Laser capture microdissection (LCM) to isolate the growth cones                                                                                                                                                                   Coupled with unbiased genomewide microarray profiling.                                                                                                                                     Many presynaptic protein mRNAs are present exclusively in old growth cones. ome receptor transcripts (e.g., EphB4), present exclusively in old growth cones, were equally abundant in young and old cell bodies.                                                                                                                                                                                     [@B235]
  No                 Cortical   Cortical and hippocampal dissociated neurons from embryonic Sprague Dawley rats at E18                                                                          *Ex vivo*      Microfluidic chamber with microgrooves (7.5 μm wide, 3 μm high)                                                                                                                                                                   Microarray                                                                                                                                                                                 Axonal transcripts are enriched for protein translational machinery, transport, cytoskeleton, and mitochondrial maintenance.                                                                                                                                                                                                                                                                         [@B200]
  No                 Motor      Primary DRG cultures from L4-5 were prepared from Sprague Dawley rats that had been injury conditioned 7 days before by sciatic nerve crush at midthigh level   *Ex vivo*      Dissociated DRGs were plated into tissue culture inserts containing porous membranes (8-μm pores). Axons were isolated after 16-20 h in culture by scraping away the cellular content from the upper or lower membrane surfaces   cDNA microarray                                                                                                                                                                            Neurotrophins (nerve growth factor, brainderived neurotrophic factor, and neurotrophin-3) regulate axonal mRNA levels and use distinct downstream signals to localize individual mRNAs.                                                                                                                                                                                                              [@B219]

Elucidation of what features of axonal function require local translation and determination of the mRNAs that mediate these functions have induced intriguing challenges in the field of axonal biology ([@B46]; [@B89]). Assessment of the axonal transcriptome using microarray studies has identified important axonal mRNAs and has demonstrated the complexity and dynamic nature of the axonal transcriptome ([@B235]; [@B70]).

In a pioneering study involving omics analysis in axons, more than 200 different mRNAs were identified with cDNA microarray analysis in axons derived from rat with injured sensory neurons ([@B219]). Proteins involved in the transcription, synthesis of proteins, intracellular transport, calcium metabolism, mitochondrial functions, and cytoskeletal functions were identified in the study ([@B219]). The report raised several important questions regarding axonal translation ([@B46]), including the question of why transcripts for nuclear proteins are localized to distal axons.

Using a microfluidic chamber enabling the isolation of axons without contamination with non-axonal material, mRNA has been purified from mature CNS axons ([@B200]). The same study also described the localization of catenin-β1 and neurexin-3 mRNA with fluorescence *in situ* hybridization in the axonal compartment ([@B200]). The somatodendritic compartments are enriched in transcripts with postsynaptic functions and in nuclear non-coding RNAs such as *7SK*, whereas transcripts related to translation such as*7SL*, the cytoplasmic non-coding RNA, are upregulated in the compartment of the axon fraction ([@B27]).

Transcriptome-wide analyses have revealed numerous transcripts encoding transmembrane or secreted proteins, which comprise about 13% of the total mRNAs found in growth cones ([@B235]). Transcripts present in axons encode many transmembrane proteins, such as integrins and protocadherins, which are cell adhesion molecules, and EphB4 and Nrp2, which are guidance receptors ([@B235]). Thus, local translation may change the cell adhesion capacity of axons and allow axons to respond to extracellular signaling molecules ([@B70]). Axons also contain transcripts that code for secreted proteins, including semaphorin and ephrin, which are guidance molecules; BMP1, CTGF, and FGF, which are growth factors; and collagen and TIMP3, which compose and regulate the extracellular matrix. Thus, it is expected that local translation probably plays a role in the regulation of extracellular components by affecting proteins that are secreted from growth cones ([@B46]). Axons also contain structures that resemble the ER and Golgi. Specific labeling of the ER and Golgi exhibits irregular, punctate staining along the axon, suggesting that axon-specific versions of these organelles may be present in nerve terminals ([@B130]).

The development of compartmentalization has enabled the examination of axon pathology in MN diseases. The knockdown of *SMN*, which encodes the protein that is deficient in spinal muscular atrophy (SMA), was shown to produce numerous transcript alterations in both axon and somatic compartments of the microarray ([@B176]). Transcripts associated with axon growth and synaptic activity are downregulated on the axonal side of *SMN*-deficient MNs. Improvements in the handling of small quantities of RNA have led to further progress in this field ([@B27]).

Evaluation of cultured spinal cord neurons grown with a compartmented platform and subjected to next-generation sequencing technology revealed that mRNAs and miRNAs are differentially expressed in the somatic compared with the axonal neuronal compartments ([@B172]). In axons with lentiviral overexpression of p.A315T *TARDBP* or p.G93A *SOD1* mutants, *Elavl2*, *miR-146a*, *miR-126-5p*, and *miR-99a* are commonly expressed. Examination of the local transcriptome revealed that the most abundant mRNAs within human embryonic stem cell-derived neuronal projections are functionally similar to the rat axonal transcriptome of cortical neurons ([@B19]).

The use of microfluidic technology has been particularly useful in neuroscience research. Microfluidic platforms have allowed researchers to address specific questions related to axonal guidance, synapse formation, and cargo transport within axons, and led to the development of three-dimensional (3D) CNS models for pharmacological testing and drug screening ([@B145]). Human iPSC-derived MNs grown in a culture device with permeable inserts were observed to produce large amounts of enriched axonal material that can be harvested for RNA isolation and sequencing ([@B117]). Transcriptome profiling has revealed axonal and somatodendritic compartment-specific expression.

Recently, Nijissen and colleagues developed a refined method named Axon-seq, combining microfluidics, RNA sequencing, and bioinformatics analysis ([@B147]). These results demonstrated that the transcriptome of the axon compartment is quite different from that of the soma and includes a smaller number of mRNAs. They identified up to 5,000 mRNAs in mouse and human stem cell-derived MN axons; the functions of the majority of these are oxidative energy and ribosome production. Axons contain transcription factor mRNAs, implicating local functions. Investigation into the response of degenerated ALS motor axons to the *SOD1*-G93A mutation identified 121 ALS-dysregulated transcripts. Among these, *Nrp1* and *Dbn1* are involved in axonal function, and *Nek1* is a known ALS-causative gene ([@B24]; [@B99]; [@B147]). Axon-seq is an advanced technique for sequencing the RNA in axons, and thus can provide enhanced knowledge about peripheral nerve biology to explain the vulnerability/resilience of MN ([@B148]; [@B5]) and to identify the treatment of MN diseases.

Development of a Microfluidic Device for Larger-Scale Omics Analysis {#S3.SS2}
--------------------------------------------------------------------

Despite the improvement offered by the microfluidic device, harvesting a sufficient volume of lysate from the axon compartment remains challenging. In the process of improving the dimensions of the well and materials, a novel microfluidic device was developed by the authors of this study ([Table 3](#T4){ref-type="table"}). The device enabled comparison of two sets of isogenic *FUS*-mutant iPSC-derived MNs generated using genome editing technology ([@B88]; [@B152]), and provided observations of increased branching in *FUS*-mutant MN axons compared with those in isogenic controls ([@B3]). This phenotype was confirmed using other ALS-causative mutations, including *SOD1* and *TARDBP*. Combining this innovative microfluidic device ([@B97]) with hiPSC-derived MN organoids further revealed the entire *in vitro* profile of the human MN axons. This technique identified increased *Fos-B* mRNA as a binding partner of FUS and as a causative event for aberrant axon morphology both *in vitro* and *in vivo*.

###### 

Comparison of our microfluidic devices with those of previous studies.

                        Neuron device                   Modified boyden              Nerve organoid device
  --------------------- ------------------------------- ---------------------------- ----------------------------
  Company               Xona Microfluidics              Corning                      Jiksak Bioengineering
  Dimension             2 D                             2 D                          3 D (axon bundle)
  Cell type             Primary mouse motor neuron      Primary mouse motor neuron   iPSCs derived motor neuron
  Pore size             1∼3 um                          3 um                         150∼200 um
  Axon length           150 um                          NA                           10,000 μm (1 cm)
  Retrievable neurons   ∼10\*3                          5 × 10\*5                    10\*4-
  RNA                   20 pg-                          0.3 ng/μl                    12 ng (l ng/μl) -
  References            [@B27]; [@B19]; [@B147], etc.   [@B172]; [@B117], etc.       [@B3]; [@B97]

Morphological changes in MN axon branching have been found to precede MN death in the mutant *SOD1*-G93A transgenic mouse model ([@B204]), and abnormal neural branching has been detected in zebrafish that overexpress mutant *FUS* ([@B9]). Improvements in axon morphology following suppression of abnormally upregulated *Fos-B* in *FUS* mutants suggested a novel therapeutic candidate for *FUS*-mutant ALS.

Previous studies have also reported that upregulation of *Fos-B* mRNA is associated with increases in spines ([@B109]; [@B32]) and growth cones ([@B6]). δ*Fos-B* modulates immature spines of the nucleus accumbens in a model of drug addiction ([@B69]). Certain chemical stimulators such as kainic acid lead to neurodegeneration via upregulated expression of immediate early genes, including that of *Fos-B* ([@B157]). The hyperexcitability hypothesis is a major theme in proposing the pathomechanism of ALS ([@B209]). A recent report of activator protein-1 (AP-1) and MN degeneration in the mutant *SOD1*-G93A transgenic mouse model has attracted attention ([@B18]). Additionally, the suppression of dual leucine zipper kinase, the upstream signal protein for c-Jun (AP-1 family member), may become a therapeutic target for ALS ([@B18]). Although substantial differences have been reported in *SOD1*-ALS compared with *FUS*-ALS and *TARDBP*-ALS ([@B62]), *SOD1*-, *TARDBP*-, and *FUS*-mutant MNs have common features, suggesting a role for AP-1 in the neurodegeneration observed in ALS. The Fos-B protein accumulates abnormally in the MNs of ALS patients, including in sporadic cases. Thus, Fos-B appears to be a potential therapeutic target molecule.

The novel microfluidic device described in the preceding paragraph comprises a large canal that enables the collection of sufficient samples of isolated MN axons for RNA sequencing ([@B97]). This device has proven useful in visualizing the global profile of the axon compartment. Although other types of microfluidic devices, some of which are specific to cell fraction analysis, are available on the market ([@B27]; [@B172]), they are typically restricted by the limited amount of specimen obtained ([Table 3](#T4){ref-type="table"}). As only a very small amount of specimen can be analyzed, variation in conditions, such as cell purity and culture procedures, may influence the results. Kawada's microfluidic device enables analysis with fewer technical biases because it involves the collection of large amounts of macroscopically observable axon bundles. RNA profiles from the axon samples have reproduced the previously reported profiles of the MN axon ([@B27]; [@B172]), justifying the methodology of this novel device. Furthermore, the data obtained may provide important resources for the subcellular fractional analysis of stem cell-derived MN axons.

Are These mRNAs Translated in Axons? {#S3.SS3}
------------------------------------

An important question is whether these mRNAs are translated in axons or transported to the nucleus/cell body. The importance of axonal translation for CNS maintenance is under debate ([@B191]). Several types of mature polarized cells utilize asymmetrical mRNA localization as a means of synaptic communication with other types of cells ([@B225]). *In vivo*, the longest axons, such as those of mature sensory and motor peripheral neurons, rely most strongly on mRNA transport and local translation to maintain homeostasis.

Upregulation of ribosome synthesis in axons has been found to occur early in the pathogenesis of both mutant *SOD1*-G93A transgenic mouse models and human ALS autopsy samples, which suggests the involvement of Schwann cells in ALS pathology and in aberrant axonal RNA metabolism ([@B208]). Gene expression analyses of the anterior branch of human obturator MNs biopsied from patients with ALS demonstrated upregulation of a cluster of genes that play important roles in biological processes involving RNA processing and protein metabolism ([@B170]).

Direct evidence for neurodegeneration has been obtained from the observation of mRNA transport dysregulation due to mutations in the RBP SMN1, which causes SMA ([@B211]). SMN is present ubiquitously, and its deletion is lethal. However, MNs are more sensitive to SMN reduction than other cell types, possibly because reduced SMN decreases the axonal localization of several mRNAs ([@B168]) and inhibits the activity of the mammalian target of rapamycin in axons ([@B108]). An additional role for SMN is in the regulation of axonal localization and local translation of *growth-associated protein 43* (*GAP43*) mRNA in growth cones ([@B54]). The overexpression of two mRNA-binding proteins, HuD and IGF2 mRNA-binding protein 1, restores the mRNA and protein levels of GAP43 and has been shown to rescue the axon outgrowth defects in the neurons of an SMA patient ([@B54]).

In previous studies, protein interaction screening intended to elucidate *FUS*-mutant phenotypes also identified several molecules that interact with FUS, including SMN ([@B227]; [@B68]). Aberrant distribution of SMN in cytosolic FUS accumulations induces SMN reduction in axons. Accumulation of mutant human FUS induces an integrated stress response and reduces protein synthesis in nearby axons ([@B116]).

Non-nuclear pools of splicing factor, proline-glutamine rich (SFPQ) are essential for normal motor development via local mRNA maintenance or processing, and the coiled-coil domain of SFPQ is required for axonal localization ([@B203]). The RBPs modulate nuclear processing, intracellular transport, and local translation of target mRNAs for an accurate spatial and temporal gene expression. SFPQ functions as an RBP because it binds to and modulates numerous neuronal mRNAs, including in cells, such as dorsal root ganglion neurons. SFPQ, which has been identified by subcellular compartmentalization analysis ([@B40]; [@B198]), has been found to orchestrate spatial gene expression, which is essential for axonal viability.

Local translation is also involved in several neurodevelopmental disorders ([@B14]). Local translation defects are associated with fragile X mental retardation and autism spectrum disorders ([@B98]). Fragile X mental retardation protein, which is present in dendritic spines, growth cones, and axons, modulates plasticity ([@B13]) and the presynaptic proteome ([@B35]; [@B2]). In mouse brain slices, loss of the fragile X mental retardation protein was found to perturb the development of presynaptic nerve terminals ([@B74]).

Degeneration of motor axons results from mutations in various tRNA synthetases, which is consistent with the notion that local translation of transported mRNA is necessary for axonal homeostasis ([@B75]; [@B194]). Recently, cytoplasmic polyadenylation element-binding protein 4 was found to orchestrate the dysregulation of mRNA expression in autism ([@B155]). Identification of a master regulator of RNA metabolism would be beneficial in understanding and treating for both diseases that affect MNs and psychiatric diseases.

Nascent chain tracking is a novel technique for visualizing local translation. This method uses multi-epitope tags and antibody-based fluorescent probes to quantify the dynamics of protein synthesis at the level of individual mRNAs ([@B137]). Due to its sensitivity and versatility, nascent chain tracking is a useful tool for quantifying mRNA translation kinetics. Synaptic activity can induce mRNA localization and the local translation of β-actin, which stabilizes expanding synapses at dendritic spines ([@B220]; [@B230]). Real-time visualization of mRNA translation in the axonal compartment is an innovative method enabling analysis of axonal pathology *in vivo* ([@B210]; [@B229]). The inducible fluorescent probe can be regulated in time and space in neurons and is used to examine the maturation of miRNA. The local maturation of miRNA by synaptic stimulation results in a spatially restricted protein synthesis reduction from the mRNA ([@B179]). The proteomics approach described in a later section adds to the understanding of the global change of nascent proteins produced in the axon fraction.

Role of Intra-Axonal Transcription Factors {#S3.SS4}
------------------------------------------

Why transcripts for nuclear proteins are localized to the distal axons is a big question raised by the omics analysis. Fos-B, a mediator of abnormal axonal branching in *FUS*-mutated MNs, is a transcription factor. Another research group also reported dysregulated transcription factors in ALS MNs ([@B147]). In determining the role of transcription factors in the axon compartment, a comprehensive transcription of the action fraction has identified mRNAs encoding a larger amount of transcription factors and co-factors ([@B84]). One example is that of axonal STAT3, which is translated locally, activated upon nerve injury, and is transported retrogradely with dynein and importin α5, modulating the survival of peripheral sensory neurons ([@B15]). Recently, *Tp53inp2* was reported to be an atypical mRNA regulating axon growth by enhancing the NGF-TrkA pathway independently with translation ([@B41]). Importantly, data have indicated that axonal degeneration shared early molecular change in the neurodegenerative process of neurological disorders in aged populations ([@B42]; [@B196]; [@B178]).

In the brain of a person with Alzheimer's disease, inhibition of local translation of *Atf4* mRNA overproduction eliminates amyloid β-induced cell loss ([@B12]; [@B156]). *Atf4* mRNA translation is controlled by phosphorylation of elongation initiation factor 2a, pivotal for an integrated stress response ([@B14]). The role of axonal transcription factors in relation to translated proteins and non-translated RNA requires further elucidation.

Interaction Among the Mechanisms Already Described {#S3.SS5}
--------------------------------------------------

The hallmark feature in the majority of autopsy cases of ALS is nuclear depletion and cytoplasmic accumulation of TDP-43 in degenerated neurons ([@B102]). Thus, dysfunctional trafficking between the nucleus and cytoplasm likely plays a role in the pathology of ALS ([@B144]) and may also be important in normal physiological aging, Huntington's disease, and Alzheimer's disease ([@B144]). RBPs with prion-like domains (PrLDs) undergo liquid-liquid phase separation to form functional liquids, which can be converted into abnormal hydrogels that contain pathological fibrils that are often seen in neurodegenerative diseases. TDP-43, FUS, heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1), and hnRNPA2 are nuclear RBPs with PrLDs that are incorrectly sent to cytoplasmic inclusions in neurodegenerative diseases. Mutations in PrLDs increase the rate of fibril formation and initiate disease ([@B71]). Karyopherin-β2, also known as transportin-1, binds the proline-tyrosine NLS and then blocks and reverses FUS, TATA-box-binding protein associated factor (TAF) 15, Ewing sarcoma RBP1 (EWSR1), hnRNPA1, and hnRNPA2 fibril formation. Importin-α and karyopherin-β1 also block and reverse TDP-43 fibril formation. Phase separation, like stress granule formation, is an emerging property of proteins containing PrLD such as FUS ([@B71]; [@B79]; [@B166]; [@B231]). T-cell-restricted intracellular antigen-1 (TIA1) mutations were found to delay stress granule disassembly and to promote the accumulation of granules harboring TDP-43 ([@B118]). *C. elegans* TIAR-2/TIA protein functions cell autonomously to inhibit axon regeneration ([@B7]). One of the important roles of phase separation is transcription enhancement ([@B177]), which might be related to local translation/transcription. The association between axonal dysfunction and these cytoplasmic events, including phase separation, has not yet been elucidated.

There is emerging evidence of interactions among different processes of axonal pathology in ALS. Annexin A11 (ANXA11), a phosphoinositide-binding protein associated with the RNA granule, has the role of a molecular tether between lysosomes and RNA granules. Such tethering is impaired by the ALS-associated *ANXA11* mutation ([@B189]; [@B113]). Late endosome bearing mRNA encoding mitochondrial functional molecules stops at mitochondria and these mRNAs are translated on Rab7a endosomes locally in the axon ([@B36]).

In summary, exactly how these complex mechanisms are influenced by each other is still unknown. There is a need for understanding how cytoskeletons are maintained, and how molecules are transported/metabolized/synthesized, or abolished when unnecessary. Elucidating the interaction of these mechanisms might answer the vital question of why MNs are vulnerable in ALS.

Advanced Omics Analysis and Further Consideration {#S3.SS6}
-------------------------------------------------

Conducting a comprehensive analysis of the newly produced proteome from limited samples of subcellular compartments that are uncontaminated by the somatodendrite remains a major technical problem ([@B53]). Stable isotope labeling of amino acids in cell culture (SILAC) has been combined with single-well solid phase-enhanced sample prep. Using this method, the newly produced proteome of isolated retinal axons was obtained rapidly (in approximately 5 min) ([@B31]). Treating axons treated with stimuli such as netrin-1, brain-derived neurotropic factor, and Sema3A, has demonstrated distinct proteomes with more than 100 different nascent proteins. Compartment analysis using pulsed SILAC may be applied to ALS cells with a sophisticated culture device.

Using an axon-TRAP-RiboTag approach in mice, the dynamic translatome of axons in the retina *in vivo* matches the subcellular function ([@B185]). The translatome of the embryonic and postnatal axons includes a changing, enriched set of genes with axon-specific roles. Thus, specific steps in axon wiring, such as axon growth, elimination of unnecessary axons, and synaptogenesis, may be present. Adult axons harbor a complicated translatome that plays a role in axon survival, neurotransmission, and neurodegenerative diseases. Mating of several ALS mouse models can help in precisely understanding mRNA dysregulation. Further transcriptome and proteome analyses using labeled growth cones of single projections in the mouse cerebral cortex *in vivo* may also be of use ([@B163]). Spatial transcriptomics is another method for elucidating gene expression in the mouse spinal cord over the disease course, and in postmortem tissue from patients with ALS ([@B123]). Another important approach is the single-cell transcriptomics of nerve organoids *in vitro* ([@B167]); pseudo-time analysis or single-cell trajectory analysis can help establish the relationship between the cause and effect of the transcriptome of the organoids ([@B223]; [@B104]). Sophisticated neuromuscular co-culture organoids would be beneficial for these studies.

Stimulated Raman scattering microscopy is a new technique for chemical imaging that can be used to map the distribution of various molecules--including lipids, proteins, and nucleic acids--in live cells and tissues, as determined by their intrinsic molecular vibration ([@B60]). The authors of this review used this type of imaging to visualize peripheral degeneration in several ALS mouse models and human postmortem tissue ([@B204]). Non-labeled live imaging of motor axons may assist in monitoring the time course of axonal pathology *in vivo*.

In clinical settings, the strength-duration time constant, which represents the hyperexcitability of an MN axon, is significantly increased in patients ([@B92], [@B93]; [@B64]). Hyperexcitability is thought to be the target of MN death in ALS ([@B209]). In cell culture settings, the shortened isoform of TDP-43 is upregulated by neuronal hyperactivation ([@B215]). The role of these short isoform of TDP-43, which might be the product of dysregulation of RNA metabolism, should be considered in the axon fraction. Recent studies have revealed the importance of stathmin-2 (STMN2), a regulator of microtubule stability, in the pathomechanism of *TARDBP* mutation ([@B105]; [@B128]). The expression of a microtubule regulator, *STMN2*, is decreased following *TARDBP* knockdown, when TDP-43 is mis-localized, and in MNs from patients and the spinal cord of postmortem samples. The reduced function of TDP-43 results in the loss of STMN2 due to altered splicing. This is functionally important, as STMN2 is necessary for the outgrowth and regeneration of MN axons. Post-translational STMN2 stabilization rescues neurite outgrowth and axon regeneration deficits by TDP-43 depletion ([@B105]). A reduction in TDP-43 inhibits axonal regeneration of iPSC-derived MNs, whereas rescue of the expression of STMN2 restores the axonal regeneration capacity ([@B128]). The effect of the short form of TDP-43 or cryptic exons under the control of TDP-43 ([@B115]) should be examined in the axon fraction.

Concluding Remarks {#S4}
==================

As described in the preceding section, advanced omics approaches, *in vivo* analysis, and axon--cytoplasmic interactions should be examined as the next steps in investigating axonal pathology in neurodegenerative disease research. The novel concept of microfluidic devices, including the nerve organoid device presented by the authors of this review, should be applied to other neuron types, co-culture systems, or proteomics analyses using human pluripotent cells, because this technique may help elucidate the resilience of long MN and the pathomechanism of ALS.
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